CN1605334A - 组合物在制备用于治疗肿瘤疾病的药物中的用途 - Google Patents

组合物在制备用于治疗肿瘤疾病的药物中的用途 Download PDF

Info

Publication number
CN1605334A
CN1605334A CNA2004100032827A CN200410003282A CN1605334A CN 1605334 A CN1605334 A CN 1605334A CN A2004100032827 A CNA2004100032827 A CN A2004100032827A CN 200410003282 A CN200410003282 A CN 200410003282A CN 1605334 A CN1605334 A CN 1605334A
Authority
CN
China
Prior art keywords
general formula
chemical compound
days
antineoplaston
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100032827A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦尼斯劳R·伯辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1605334A publication Critical patent/CN1605334A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CNA2004100032827A 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途 Pending CN1605334A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
US09/121567 1998-07-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB99811314XA Division CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物

Publications (1)

Publication Number Publication Date
CN1605334A true CN1605334A (zh) 2005-04-13

Family

ID=22397538

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2004100032827A Pending CN1605334A (zh) 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用
CNB99811314XA Expired - Fee Related CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用
CNB99811314XA Expired - Fee Related CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100399658B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ES2333337T3 (es) * 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
ES2928586T3 (es) 2009-04-03 2022-11-21 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos para elaborar el mismo
KR101715008B1 (ko) 2009-06-08 2017-03-22 유씨엘 비즈니스 피엘씨 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
PL213698B1 (pl) 2013-04-30
JP2011051993A (ja) 2011-03-17
KR20030027089A (ko) 2003-04-03
ATE257378T1 (de) 2004-01-15
KR100417100B1 (ko) 2004-02-05
ES2214866T3 (es) 2004-09-16
US6943192B2 (en) 2005-09-13
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
WO2000004894A3 (en) 2000-04-27
DE69914084D1 (de) 2004-02-12
CN1319010A (zh) 2001-10-24
AU4854299A (en) 2000-02-14
WO2000004894A2 (en) 2000-02-03
DE69914084T2 (de) 2004-10-28
PL345959A1 (en) 2002-01-14
CA2336945A1 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
KR20030027087A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
IL140848A0 (en) 2002-02-10
HK1037142A1 (en) 2002-02-01
EA200100168A1 (ru) 2001-08-27
US20010044466A1 (en) 2001-11-22
KR100414587B1 (ko) 2004-01-13
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
IL140848A (en) 2005-05-17
EA004179B1 (ru) 2004-02-26
CA2336945C (en) 2008-11-18
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
NZ509244A (en) 2004-02-27
KR20030027088A (ko) 2003-04-03
CN100400039C (zh) 2008-07-09
AU759278B2 (en) 2003-04-10
EP1098643A2 (en) 2001-05-16
ZA200100622B (en) 2002-06-26
DK1098643T3 (da) 2004-05-24
KR100417101B1 (ko) 2004-02-05
ID28160A (id) 2001-05-10

Similar Documents

Publication Publication Date Title
CN1605334A (zh) 组合物在制备用于治疗肿瘤疾病的药物中的用途
CN1348436A (zh) 新颖的核受体ppar配体
US11464794B2 (en) Composition of alginic oligosaccharic diacids
CN1471390A (zh) 用于治疗内皮机能障碍的非诺贝特和辅酶q10 组合物
CN1195728C (zh) 治疗糖尿病和相关病症的新的化合物
CN1638756A (zh) 左旋(r)班布特罗及其药物用途
CN112121041B (zh) 金属络合物的新应用
CN1186336C (zh) 秦皮总香豆素的制备方法及其在制药中的应用
CN1284056A (zh) 抗惊厥和中枢神经系统活性的双(氟苯基)烷基酰胺
CN101032504A (zh) 甘草苷在制药中的应用
CN1533277A (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CN1878557A (zh) 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物
CN1230178C (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
CN1133626C (zh) 双氯芬酸偶联衍生物、其合成方法及抗炎作用
CN1908001A (zh) 胆汁酸衍生物及其医药用途
JP2016505054A (ja) 放射線損傷を防止し、放射線により損傷された組織の再生と修復を促進する薬剤の調製における、飽和アミン系化合物の応用
CN101066982A (zh) 氨基酸－葡萄糖衍生物的99mTc配合物及其制备方法
CN1301253C (zh) 五元硫杂环类化合物及其用于制备治疗和预防肥胖相关疾病的药物的用途
CN105439889B (zh) 一种香兰素胺类新化合物、其制备方法及医药用途
CN115836047B (zh) 一种芳基丙酸衍生物及其乳状制剂
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease
CN115557839B (zh) 一种包含芳基丙酸衍生物的脂肪乳剂及其制备方法
CN1511840A (zh) 含水溶性基团的葛根素化合物及其制法和用途
CN1361111A (zh) 呋甾皂甙的类似物、分离方法和用途
CN1844106A (zh) 羟苯磺酸烷基吡嗪药物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074771

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074771

Country of ref document: HK